{'fraction_non_alphanumeric': 0.02206177296430004, 'fraction_numerical': 0.02727637384677096, 'mean_word_length': 4.923990498812351, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Thank You JAMA Oncology Authors, Peer Reviewers, and Readers.

We have completed JAMA Oncology’s inaugural year and would like to thank our authors, reviewers, and readers for the significant contributions made to the journal over the past year. The editorial board and I are honored to have the opportunity to serve the oncology community and provide access to new discoveries and state-of-the-art educational materials that will influence and benefit the treatment and lives of our patients. First, I would like to thank our authors. In 2015, we received 1355 manuscript submissions, including 766 original investigations, 55 clinical trial reports, and 57 metaanalyses. The 66 submitted reviews covered topics ranging from the newest treatment for metastatic breast cancer1 to the genomics of chronic lymphocytic leukemia.2 The quality of our published manuscripts is reflected in the 482 000 users who have come to our website to access content and more than 9500 media mentions of JAMA Oncology articles in print, online, and news services this past year. In 2015, the acceptance rate for Original Investigations was 12%, 23% for clinical trials, and 12% for meta-analyses. We accepted 27% of Review articles, 33% of submitted Research Letters, 42% of Viewpoints, and 44% of Clinical Challenges. JAMA Oncology is now indexed in PubMed and, as a new journal, we expect our first impact factor designation in 2017. More detailed statistics are displayed in the Table. We are also very grateful to our peer reviewers, from several continents, and acknowledge their contribution to JAMA Oncology by publishing the names of more than 700 experts who have completed a manuscript review this year.3 This group of renowned laboratory, clinical, and quantitative scientists completed external peer review in a median time of 13 days. Their efforts have allowed JAMA Oncology to maintain a median time from receipt of an original research report to acceptance of 33 days. Our median time from acceptance to first publication is 56 days. The ability to rapidly review and publish papers within 60 days of receipt ensures that important findings are available to the oncology community as quickly as possible. We would not be able to provide this service without our expert peer reviewers and their commitment to the timely turnaround of critiques. Finally, we would like to thank our readers. Print copies of JAMA Oncology are distributed to 14 000 recipients each month, and we provide our Table of